Skip to main content

Table 2 Association of HIV status and prevalent pulmonary outcomes for each cohort

From: Pulmonary symptoms and diagnoses are associated with HIV in the MACS and WIHS cohorts

 

MACS

WIHS

 

PR (95% CI) for HIV-infected

p-value

PR (95% CI) for HIV-infected

p-value

Symptoms

    

  Cough

1.11 (1.01-1.21)

0.03

1.02 (0.95-1.09)

0.61

  Dyspnea

1.25 (1.02-1.53)

0.03

1.09 (0.98-1.20)

0.12

  Wheeze

1.20 (1.00-1.44)

0.04

1.19 (1.03-1.38)

0.02

  Sputum

1.08 (0.97-1.20)

0.18

1.08 (0.98-1.19)

0.11

  Any symptom

1.11 (1.04-1.19)

0.003

1.04 (0.99-1.10)

0.12

  Inhaler use

1.17 (0.99-1.38)

0.06

1.14 (1.00-1.30)

0.04

  Oxygen use

1.12 (0.57-2.19)

0.75

3.43 (1.36-8.66)

0.01

Diagnostic testing

    

  Sputum testing

2.93 (2.24-3.83)

<0.001

2.88 (2.13-3.89)

<0.001

  Bronchoscopy

2.73 (1.75-4.28)

<0.001

1.67 (0.94-2.98)

0.08

  Chest CT

1.28 (1.11-1.47)

0.001

1.24 (1.00-1.53)

0.05

  Pulmonary function tests

1.04 (0.92-1.17)

0.55

0.97 (0.82-1.15)

0.76

  Echocardiogram

1.27 (1.11-1.46)

0.001

1.02 (0.83-1.27)

0.82

  Polysomnography

1.30 (1.06-1.59)

0.01

1.33 (0.92-1.93)

0.13

Diagnoses

    

  Asthma

1.04 (0.80-1.34)

0.78

1.05 (0.88-1.25)

0.57

  Sleep apnea

1.42 (1.10-1.84)

0.01

2.10 (1.31-3.36)

0.002

  Any COPD

1.31 (0.80-2.14)

0.28

1.35 (0.82-2.24)

0.24

  1. Models are adjusted for age, race, smoking status, pack-years smoked, intravenous drug use, and other factors noted to be significantly associated with the outcome (p < 0.05) in stepwise regression.
  2. MACS - Multicenter AIDS Cohort Study; WIHS - Women’s Interagency HIV Study; PR - Prevalence ratio; CI - confidence intervals; CT – computed tomography; COPD - chronic obstructive pulmonary disease.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us